Natural Product (NP) Details
General Information of the NP (ID: NP5783) | |||||
---|---|---|---|---|---|
Name |
Toremifene
|
||||
Synonyms |
toremifene; Farestone; 89778-26-7; Toremifeno; Toremifenum; UNII-7NFE54O27T; GTx-006; Z-Toremifene; {2-[4-(4-Chloro-1,2-diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine; 7NFE54O27T; CHEBI:9635; Toremifenum [Latin]; Toremifeno [Spanish]; 89778-26-7 (free base); 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Ethanamine, 2-(4-((1Z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-; Toremifene Base; GTx 006; Toremifene [INN:BAN]; Estrimex; Toremifene (INN); C26H28ClNO; CCRIS 8745; (E)-Toremifene; 89778-29-0; (Z)-2-(4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; 2-(para-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine (IUPAC); SCHEMBL7465; CHEMBL1655; BIDD:PXR0202; BIDD:ER0222; BIDD:GT0211; GTPL4325; DTXSID3023689; BDBM58492; cid_3005572; HY-B0005A; HMS2090B22; HMS3714P06; BBL029023; DL-519; MFCD00801070; STK626445; ZINC12404516; AKOS005559276; AC-1751; CCG-220952; CS-1268; DB00539; 2-({4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-N,N-dimethylethanamine; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethan-1-amine; Ethanamine, 2-(4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, (Z)-; MRF-0000351; NCGC00160530-02; NCGC00160530-13; J33.157K; K600; SBI-0206902.P001; 78T267; C08166; D08620; W-5124; 29515-EP2272827A1; 29515-EP2275420A1; 29515-EP2280012A2; 29515-EP2281815A1; 29515-EP2295055A2; 29515-EP2295416A2; 29515-EP2295426A1; 29515-EP2295427A1; 29515-EP2298748A2; 29515-EP2298764A1; 29515-EP2298765A1; 29515-EP2301933A1; 29515-EP2305640A2; 29515-EP2305642A2; 29515-EP2305671A1; 29515-EP2311453A1; 29515-EP2311808A1; 29515-EP2311825A1; 29515-EP2311827A1; 29515-EP2311829A1; 29515-EP2311840A1; 29515-EP2311842A2; AB00698360-07; AB00698360-09; AB00698360-10; AB00698360_11; AB00698360_12; A843306; Q3993743; SR-01000763502-5; BRD-K51350053-048-06-6; (2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine; 2-[4-[(Z)-4-chloranyl-1,2-diphenyl-but-1-enyl]phenoxy]-N,N-dimethyl-ethanamine; 2-[4-[(Z)-4-chloro-1,2-di(phenyl)but-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-[4-[(Z)-4-chloro-1,2-diphenyl-but-1-enyl]phenoxy]ethyl-dimethyl-amine;citric acid; 2-[4-[(Z)-4-chloranyl-1,2-diphenyl-but-1-enyl]phenoxy]-N,N-dimethyl-ethanamine;2-oxidanylpropane-1,2,3-tricarboxylic acid; 275360-73-1; T0R
Click to Show/Hide
|
||||
Species Origin | Homo sapiens ... | Click to Show/Hide | |||
Homo sapiens | |||||
Disease | Breast cancer [ICD-11: 2C60] | Approved | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C26H28ClNO
|
||||
PubChem CID | |||||
Canonical SMILES |
CN(C)CCOC1=CC=C(C=C1)C(=C(CCCl)C2=CC=CC=C2)C3=CC=CC=C3
|
||||
InChI |
1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-
|
||||
InChIKey |
XFCLJVABOIYOMF-QPLCGJKRSA-N
|
||||
CAS Number |
CAS 89778-26-7
|
||||
ChEBI ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Atamestane | Breast cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
Experimental
Result(s) |
Combination of toremifene plus atamestane was as effective as toremifene or tamoxifen alone but may not provide any additional benefit over toremifene alone or tamoxifen alone. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Estrogen receptor (ESR) | Molecule Info | [3] | |
KEGG Pathway | Estrogen signaling pathway | Click to Show/Hide | ||
2 | Prolactin signaling pathway | |||
3 | Thyroid hormone signaling pathway | |||
4 | Endocrine and other factor-regulated calcium reabsorption | |||
5 | Proteoglycans in cancer | |||
NetPath Pathway | FSH Signaling Pathway | Click to Show/Hide | ||
2 | EGFR1 Signaling Pathway | |||
3 | RANKL Signaling Pathway | |||
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
2 | Signaling events mediated by HDAC Class II | |||
3 | Plasma membrane estrogen receptor signaling | |||
4 | LKB1 signaling events | |||
5 | Regulation of Telomerase | |||
6 | ATF-2 transcription factor network | |||
7 | AP-1 transcription factor network | |||
8 | FOXM1 transcription factor network | |||
9 | Validated nuclear estrogen receptor alpha network | |||
10 | Signaling mediated by p38-alpha and p38-beta | |||
11 | FOXA1 transcription factor network | |||
Reactome | Nuclear signaling by ERBB4 | Click to Show/Hide | ||
2 | Nuclear Receptor transcription pathway | |||
WikiPathways | Estrogen signaling pathway | Click to Show/Hide | ||
2 | Nuclear Receptors Meta-Pathway | |||
3 | Estrogen Receptor Pathway | |||
4 | Signaling by ERBB4 | |||
5 | JAK/STAT | |||
6 | Integrated Pancreatic Cancer Pathway | |||
7 | Leptin signaling pathway | |||
8 | miR-targeted genes in muscle cell - TarBase | |||
9 | Integrated Breast Cancer Pathway | |||
10 | Nuclear Receptors |
